Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis
Ist Teil von
Oncotarget, 2017-12, Vol.8 (64), p.107513-107529
Ort / Verlag
United States: Impact Journals LLC
Erscheinungsjahr
2017
Link zum Volltext
Quelle
EZB Free E-Journals
Beschreibungen/Notizen
To provide better insight into the genetic signatures of neuroblastomas, we analyzed 500 neuroblastomas (included specimens from JNBSG) using targeted-deep sequencing for 10 neuroblastoma-related genes and SNP arrays analysis. ALK expression was evaluated using immunohistochemical analysis in 259 samples. Based on genetic alterations, the following 6 subgroups were identified: groups A (
abnormalities), B (other gene mutations), C (
amplification), D (11q loss of heterozygosity [LOH]), E (at least 1 copy number variants), and F (no genetic changes). Groups A to D showed advanced disease and poor prognosis, whereas groups E and F showed excellent prognosis. Intriguingly, in group A,
amplification was not a significant prognostic marker, while high ALK expression was a relevant indicator for prognosis (
= 0.033). Notably, the co-existence of
amplification and 1p LOH, and the co-deletion of 3p and 11q were significant predictors of relapse (
= 0.043 and
= 0.040). Additionally, 6q/8p LOH and 17q gain were promising indicators of survival in patients older than 5 years, and 1p, 4p, and 11q LOH potentially contributed to outcome prediction in the intermediate-risk group. Our genetic overview clarifies the clinical impact of genetic signatures and aids in the better understanding of genetic basis of neuroblastoma.